Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-κB and MAPK signal pathways

Journal of Molecular Histology

Volumn 46, Issue 3, 2015, Pages 283-290

  Wang, Wei ^a   Zhou, Pang hu ^a   Xu, Chang geng ^a   Zhou, Xiang jun ^a   Hu, Wei ^a   Zhang, Jie ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUBEI POLYTECHNIC UNIVERSITY   (China)

Author keywords

Baicalein; CKDs; Inflammation; MAPK; NF B

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; BAICALEIN; CD3 ANTIGEN; CD68 ANTIGEN; COLLAGEN TYPE 1; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; FLAVANONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION INHIBITION; MALE; MOUSE; NONHUMAN; OBSTRUCTION-INDUCED RENAL FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FIBROSIS; KIDNEY; METABOLISM; PATHOLOGY; PRECLINICAL STUDY; RENAL INSUFFICIENCY, CHRONIC;

MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG EVALUATION, PRECLINICAL; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; FLAVANONES; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; NF-KAPPA B; RENAL INSUFFICIENCY, CHRONIC;

EID: 84930485476     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-015-9621-8     Document Type: Article

References (35)

1. Bani-Hani AH et al (2009) IL-18 neutralization ameliorates obstruction-induced epithelial–mesenchymal transition and renal fibrosis. Kidney Int 76:500–511. doi:10.1038/ki.2009.216
2. Boutet A, De Frutos CA, Maxwell PH, Mayol MJ, Romero J, Nieto MA (2006) Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J 25:5603–5613. doi:10.1038/sj.emboj.7601421
3. Crisman JM, Richards LL, Valach DP, Franzoni DF, Diamond JR (2001) Chemokine expression in the obstructed kidney. Exp Nephrol 9:241–248
4. de Borst MH et al (2009) c-Jun NH2-terminal kinase is crucially involved in renal tubulo-interstitial inflammation. J Pharmacol Exp Ther 331:896–905. doi:10.1124/jpet.109.154179
5. Eddy AA (2014) Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl 4:2–8. doi:10.1038/kisup.2014.2
6. Eddy AA, Lopez-Guisa JM, Okamura DM, Yamaguchi I (2012) Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol 27:1233–1247. doi:10.1007/s00467-011-1938-2
7. Esteban V et al (2004) Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. JASN 15:1514–1529
8. Fan JM, Huang XR, Ng YY, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY (2001) Interleukin-1 induces tubular epithelial-myofibroblast trans differentiation through a transforming growth factor-beta1-dependent mechanism in vitro. Am J kidney Dis 37:820–831
9. Gao Y, Lu J, Zhang Y, Chen Y, Gu Z, Jiang X (2013) Baicalein attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of miR-21. Pulm Pharmacol Ther 26:649–654. doi:10.1016/j.pupt.2013.03.006
10. Hou YC, Lin SP, Tsai SY, Ko MH, Chang YC, Chao PD (2011) Flavonoid pharmacokinetics and tissue distribution after repeated dosing of the roots of Scutellaria baicalensis in rats. Planta Med 77:455–460. doi:10.1055/s-0030-1250433
11. Inoue T, Jackson EK (1999) Strong antiproliferative effects of baicalein in cultured rat hepatic stellate cells. Eur J Pharmacol 378:129–135
12. Jones LK et al (2009) IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol Dial Transplant 24:3024–3032. doi:10.1093/ndt/gfp214
13. Klahr S, Morrissey J (2002) Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283:F861–F875. doi:10.1152/ajprenal.00362.2001
14. Kong EK, Yu S, Sanderson JE, Chen KB, Huang Y, Yu CM (2011) A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats. Eur J Pharmacol 658:175–181. doi:10.1016/j.ejphar.2011.02.033
15. Lee SB, Kalluri R (2010) Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 78:S22–S26. doi:10.1038/ki.2010.418
16. Liu Y (2011) Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7:684–696. doi:10.1038/nrneph.2011.149
17. Liu A et al (2014) Baicalein protects against polymicrobial sepsis-induced liver injury via inhibition of inflammation and apoptosis in mice. Eur J Pharmacol 748C:45–53. doi:10.1016/j.ejphar.2014.12.014
18. Ni H, Chen J, Pan M, Zhang M, Zhang J, Chen P, Liu B (2013) FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease. J Mol Histol 44:693–703. doi:10.1007/s10735-013-9521-8
19. Nightingale J, Oncostatin M et al (2004) A cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. JASN 15:21–32
20. Oh KS, Oh BK, Park CH, Mun J, Won SH, Lee BH (2012) Baicalein potently inhibits Rho kinase activity and suppresses actin stress fiber formation in angiotensin II-stimulated H9c2 cells. Biol Pharm Bull 35:1281–1286
21. Panzer U et al (2009) Resolution of renal inflammation: a new role for NF-kappaB1 (p50) in inflammatory kidney diseases American journal of physiology. Renal Physiol 297:F429–F439. doi:10.1152/ajprenal.90435.2008
22. Ricardo SD, van Goor H, Eddy AA (2008) Macrophage diversity in renal injury and repair. J Clin Investig 118:3522–3530. doi:10.1172/JCI36150
23. Rodriguez-Pena AB, Grande MT, Eleno N, Arevalo M, Guerrero C, Santos E, Lopez-Novoa JM (2008) Activation of Erk1/2 and Akt following unilateral ureteral obstruction. Kidney Int 74:196–209. doi:10.1038/ki.2008.160
24. Schreiner GF, Harris KP, Purkerson ML, Klahr S (1988) Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. Kidney Int 34:487–493
25. Shimizu I (2000) Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. J Gastroenterol Hepatol 15(Suppl):D84–D90
26. Shimizu I (2001) Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord 1:227–240
27. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ (2004) The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. JASN 15:370–379
28. Sun H, Che QM, Zhao X, Pu XP (2010) Antifibrotic effects of chronic baicalein administration in a CCl4 liver fibrosis model in rats. Eur J Pharmacol 631:53–60. doi:10.1016/j.ejphar.2010.01.002
29. Tashiro K et al (2003) Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB. Int J Mol Med 12:587–592
30. Vielhauer V, Kulkarni O, Reichel CA, Anders HJ (2010) Targeting the recruitment of monocytes and macrophages in renal disease. Semin Nephrol 30:318–333. doi:10.1016/j.semnephrol.2010.03.006
31. Wang YGM, Sun S, Dai J, Cao H, Zheng N, Fang J, Gou X, Lu X, Zhang Y (2012) The effects of baicalein on rat renal fibrosis and the experssions of TGF-β1 and Smad-2 (in Chinese). J Chang Univ Tradit Chin Med 28:383–385
32. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP (2009) Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15:416–428. doi:10.1016/j.ccr.2009.03.016
33. Wu K, Li H, Tian J, Lei W (2014) Protective effect of baicalein on renal ischemia/reperfusion injury in the rat. Renal Fail 1–7. doi:10.3109/0886022X.2014.991999
34. Zhang X et al (2014) Baicalein ameliorates inflammatory-related apoptotic and catabolic phenotypes in human chondrocytes. Int Immunopharmacol 21:301–308. doi:10.1016/j.intimp.2014.05.006
35. Zheng X et al. (2013) Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: role of NF-kappa B signaling. Eur J Pharmacol. doi:10.1016/j.ejphar.2013.10.034